CSIMarket Company Name, Ticker, Competitors, else..
 
Pharvaris N v   (NASDAQ: PHVS)
 
Price: $31.5400 $-0.18 -0.567%
Day's High: $31.979999542236328 Week Perf: -1.5 %
Day's Low: $ 31.50 30 Day Perf: -9.71 %
Volume (M): 22,754 52 Wk High: $ 43.25
Volume (M$): $ 0 52 Wk Avg: $29.06
Open: $31.74 52 Wk Low: $20.65



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 35
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -248
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Pharvaris N v refers to a specific legal case involving Pharvaris, a biopharmaceutical company, as the plaintiff. The N v generally denotes a lawsuit where the defendant is not specified or is yet to be determined. Therefore, Pharvaris N v indicates that Pharvaris is the plaintiff in a pending legal action or lawsuit, but the specific details or parties involved in the case are not provided.


   Company Address: Emmy Noetherweg 2 Leiden 2333
   Company Phone Number: 71 2036 410   Stock Exchange / Ticker: NASDAQ PHVS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

Published Mon, Jun 2 2025 10:56 AM UTC

Pioneering Advances in Bradykinin-Mediated Angioedema: Pharvaris Unveils Promising Data on DeucrictibantIn a significant stride towards addressing the unmet medical needs of patients with bradykinin-mediated disorders, Pharvaris, a late-stage biopharmaceutical company, has recently presented compelling data supporting the ongoing clinical development of its innovative oral ...
Product Service News

Pharvaris Gains Orphan Designation from European Commission for Deucrictibant in Angioedema Treatment,

Published Tue, Apr 1 2025 11:03 AM UTC

ZUG, Switzerland April 1, 2025 Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing innovative therapies for bradykinin-mediated diseases, has announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant. This designation is aimed at facilitating the treatment of conditions such as her...
Management Announcement

Pharvaris Unveils 2025 Strategic Priorities Amid Financial Struggles, Highlighting Innovations in Hereditary Angioedema Treatment.

Published Mon, Jan 13 2025 11:50 AM UTC

Pharvaris Charts a Course for Strategic Growth Amidst Financial ChallengesOverview of Pharvaris’ Strategic Vision for 2025ZUG, Switzerland – On January 13, 2025, Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, unveiled its strategic priorities for the coming year. With a focus on addressing the unmet needs of patients suffering from bradykinin-mediate...
Clinical Study

Pharvaris (Nasdaq PHVS), a biopharmaceutical company focused on developing new oral treatments ...

Published Thu, Sep 5 2024 10:49 AM UTC

Pharvaris Presents Encouraging Long-Term Data on Deucrictibant at Bradykinin Symposium 2024 Pharvaris (Nasdaq: PHVS), a biopharmaceutical company focused on developing new oral treatments for hereditary angioedema (HAE), has recently revealed promising long-term extension data for its drug, deucrictibant. The results were presented at the Bradykinin Symposium 2024, which too...
Clinical Study

Pharvaris Receives Noteworthy Acceptance to Present Critical Clinical Data at Triad of Prestigious International Congresses

Published Mon, May 13 2024 10:50 AM UTC

ZUG, Switzerland - The late-stage biopharmaceutical enterprise with operations in Zug, Switzerland, Pharvaris, renowned for its development of groundbreaking, oral bradykinin B2 receptor antagonists to curb and prohibit hereditary angioedema (HAE) attacks, added a new feather to its cap as it proclaimed the endorsement of abstracts slated for demonstration at three reputed, ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 57.03
Working Capital Ratio 57.03
Leverage Ratio (MRQ) 0.13
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.83 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -7,096,159
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.